ABBV
:NYSE

Add to watchlist
$108.50
Last updated:10/25/2021
ABBV: NYSE
$108.50
AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat…

Dividend yield
4.79%
$5.20 anually
P/E ratio
29.26x
vs. 7.87x forward
Payout ratio
140.24%
Yearly
CASH payout ratio
Last quarter
Become our supporter to unlock all data!
Stock volatility (Beta)
past 12 months
Become our supporter to unlock all data!
ABBV dividends
Create free account to unlock
Company results
Qtr
Ann
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Stock exposure in ETFs
ETF
Percentage of ETF
Become a premium member and see all 91 ETFs that include this stock
Company profile
CEO
Mr. Richard A. Gonzalez
Market capitalization
Mega (191.74B)
ABBV price history